Association between endometrial cancer and tamoxifen treatment of breast cancer

Breast Cancer Research and Treatment

Volumn 54, Issue 3, 1999, Pages 255-260

  Peters Engl, Christian ^a   Frank, Wilhelm ^d   Danmayr, Eberhard ^b   Friedl, Hans P ^c   Leodolter, Sepp ^b   Medl, Michael ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c Austrian Central Statistical Office   (Austria)

^d Ludwig Boltzmann I for G O/R M ^*

Author keywords

Breast cancer; Endometrial cancer; Tamoxifen

Indexed keywords

ANTIESTROGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS;

EID: 0033034261     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006126411210     Document Type: Article

References (40)

1. 1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 71-85, 1992
2. 2. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet ii: 171-175, 1987
3. 3. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov N, Wolmark N, Wickerham DL, Fisher ER, Margolcse R, Robioux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrer W, Evans J, Lickley HL, Ketner M: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320: 479-484, 1989
4. 4. Love RR: Tamoxifen prophylaxis in breast cancer. Oncology (Willston Park) 6: 33-43, 1992
5. 5. Fisher B, Redmond C: New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventing agent. J Natl Cancer Inst 83: 1278-1280, 1991
6. 6. Powles TJ: The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 340: 1145-1147, 1992
7. 7. Fomander T, Rutqvist LE, Cedermark B, Glas U, Mattson A, Silverswärd C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet i: 117-120, 1989
8. 8. Gusberg SB: Tamoxifen for breast cancer: associated endometrial cancer. Cancer 65: 1463-1464, 1990
9. 9. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69: 237-238, 1985
10. 10. Jordan VC: Tamoxifen and endometrial cancer. Lancet ii: 1019, 1988
11. 11. Hardell L: Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet ii: 563, 1988
12. 12. Atlante G, Pozzi M, Vincenzoni C, Vocature G: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37: 378-380, 1990
13. 13. Malfetano JH: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 39: 82-84, 1990
14. 14. Spinelli G, Bardazzi N, Citernesi A, Fontanarosa M, Curiel P: Endometrial carcinoma in tamoxifen-treated breast cancer patients. J Chemother 3: 267-270, 1991
15. 15. De Muylder X, Neven P, De Sommer M, Van Belle Y, Vanderick G, De Muylder E: Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36: 127-130, 1991
16. 16. Van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimrere CHF, Otter R, Schouten LJ, Damhuis RAM, Bontenbal M, Diepenhorst FW, van den Belt-Dusebout AW, van Tinteren H: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994
17. 17. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschmann RJ: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 90: 207-208, 1990
18. 18. Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013-1017, 1991
19. 19. Andersson M, Storm HH, Mouridsen HT: Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 31: 259-263, 1992
20. 20. Seud MAF, Johnson J, Weed JC: Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 82(2): 165-169, 1993
21. 21. Stewart H, Knight GM: Tamoxifen and the uterus and endometrium. Lancet 1: 375-376, 1989
22. 22. Neven P, De Muylder X, VanBelle Y, Vanderick G, De Muylder E: Tamoxifen and the uterus and endometrium. Lancet i: 375, 1989
23. 23. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single agent in the management of early breast cancer. Br J Cancer 57: 608-611, 1988
24. 24. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS: Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83: 1450-1459, 1991
25. 25. Ribeiro G, Swindell R: The Christic hospital adjuvant tamoxifen trial - status at 10 years. Br J Cancer 57: 601-603, 1988
26. 26. Bundesministerium für Gesundheit, Sport und Konsumentenschutz: Krebsstatistik. Bericht über das Gesundheitswesen in Österreich im Jahre 1993. Österreichische Staatsdruckerei, Wien, 1994
27. 27. Kurman RJ: Blaustein's Pathology of the Female Genital Tract, 3rd edn. Springer-Verlag, New York, 1987
28. 28. Creasman WT: New gynecologic cancer staging. Obstet Gynecol 75: 287-288, 1990
29. 29. American Joint Committe on Cancer: Handbook for Staging of Cancer, 4th edn. J. B. Lippincott Company, Philadelphia, 1993
30. 30. Kleinbaum DG, Kuppes LL, Morgenstern H: Epidemiologic Research. Van Nostrand Reinhold, New York, 1991
31. 31. Woolf B: On estimating the relationship between blood group and disease. Annals Human Genet 19: 251-253, 1955
32. 32. Peters-Engl CH, Medl M, Danmayr E, Mirau M, Alth G, Leodolter S: Endometrial cancer after tamoxifen treatment: a descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer. Anticancer Res 16: 3241-3246, 1996
33. 33. Margriples U, Naftolin F, Schwartz PE, Carcangiu ML: Highgrade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Ocol 11: 485-490, 1993
34. 34. Boccardo F, Bruzzi P, Rubagotti A, Nicolo G, Rosso R: Estrogen-like action of tamoxifen on vaginal epithelial in breast cancer patients. Oncology 38: 281-285, 1981
35. 35. Patterson JS: Clinical aspects and development of antiestrogen therapy: a review of the endocrine effects of tamoxifen in animals and man. J Endocrinol 89: 67-75, 1981
36. 36. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812-815, 1988
37. 37. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Adjuvant Breast and Bowel Project (NSAPB-14). J Natl Cancer Inst 86: 527-537, 1994
38. 38. Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR: Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87: 1359-1364, 1995
39. 39. Cohen I, Doron JD, Rosen JD, Shapira J, Cordoba M, Gilboa S, Altaras MM, Yigael D, Beyth Y: Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52(2): 185-190, 1994
40. 40. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S: Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318-1321, 1994